| Literature DB >> 32160878 |
Mitsuhiro Tambo1, Satoru Taguchi2, Yu Nakamura2, Takatsugu Okegawa2, Hiroshi Fukuhara2.
Abstract
BACKGROUND: Acute pyelonephritis (APN) with obstructive uropathy often causes sepsis. Recently, sepsis was redefined using the sequential organ failure assessment (SOFA) score, based on the new Sepsis-3 criteria. We investigated predictors for sepsis using this new definition in patients with obstructive APN associated with upper urinary tract calculi.Entities:
Keywords: Acute pyelonephritis; Presepsin; Procalcitonin; Sepsis; Upper urinary tract calculi
Mesh:
Substances:
Year: 2020 PMID: 32160878 PMCID: PMC7066822 DOI: 10.1186/s12894-020-00596-4
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
PCT and PSEP stratified by AKI grade according to the AKIN criteria
| Variables | AKI grade | ||||
|---|---|---|---|---|---|
| Grade 0 ( | Grade 1 ( | Grade 2 ( | Grade 3 ( | ||
| PCT, median (ng/mL) | 0.40 | 1.89 | 84.45 | 113.46 | 0.015 |
| PSEP, median (pg/mL) | 335 | 528 | 835 | 740 | 0.001 |
PCT Procalcitonin, PSEP Presepsin, AKI Acute kidney injury, AKIN Acute kidney injury network
Fig. 1Flow chart representing the diagnostic process of sepsis according to the Sepsis-3 criteria
Characteristics of patients with and without sepsis
| Variables | Sepsis group | Non-sepsis group | |||||
|---|---|---|---|---|---|---|---|
| n | % | n | % | ||||
| Patients | 11 | 50 | |||||
| Age (yr) | Median [IQR] | 73 [55–77] | 61 [52–76] | 0.209 | |||
| Gender | Male | 3 | 27.3 | 21 | 42.0 | ||
| Female | 8 | 72.7 | 29 | 58.0 | 0.365 | ||
| Performance status | 0, 1 | 9 | 81.8 | 47 | 94.0 | ||
| 2, 3 | 2 | 18.2 | 3 | 6.0 | 0.182 | ||
| Diabetes mellitus | Negative | 8 | 72.7 | 37 | 74.0 | ||
| Positive | 3 | 27.3 | 13 | 26.0 | 0.931 | ||
| Cardiovascular or neurologic disease | Negative | 7 | 63.6 | 42 | 84.0 | ||
| Positive | 4 | 36.4 | 8 | 16.0 | 0.124 | ||
| Immunocompromised status | Negative | 10 | 90.9 | 48 | 96.0 | ||
| Positive | 1 | 9.1 | 2 | 4.0 | 0.480 | ||
| CCI scores | 0–2 | 8 | 72.7 | 47 | 94.0 | ||
| ≥3 | 3 | 27.3 | 3 | 6.0 | 0.066 | ||
| Serum creatinine (mg/dL) | Median [IQR] | 1.50 [1.22–2.14] | 1.17 [0.78–1.70] | 0.058 | |||
| Leukocyte counts (×103/μL) | Median [IQR] | 18.3 [10.0–22.3] | 12.8 [10.1–15.5] | 0.073 | |||
| C-reactive protein (mg/dL) | Median [IQR] | 14.17 [4.84–24.51] | 10.72 [6.66–16.34] | 0.586 | |||
| Platelet counts (× 104/μL) | Median [IQR] | 10.1 [6.1–14.8] | 19.2 [15.5–26.9] | 0.001 | |||
| Serum albumin (g/dL) | Median [IQR] | 3.0 [2.6–3.5] | 3.6 [3.2–4.0] | 0.016 | |||
| PCT (ng/mL) | Median [IQR] | 31.57 [1.83–134.40] | 0.54 [0.14–4.86] | < 0.001 | |||
| PSEP (pg/mL) | Median [IQR] | 1080 [696–1550] | 387 [313–558] | < 0.001 | |||
| Midstream urine culture | Negative | 0 | 0.0 | 7 | 14.0 | ||
| Positive | 11 | 100.0 | 43 | 86.0 | 0.187 | ||
| Blood culture | Negative | 1 | 9.1 | 38 | 76.0 | ||
| Positive | 10 | 90.9 | 12 | 24.0 | < 0.001 | ||
| Hydronephrosis | Low-grade | 7 | 63.6 | 32 | 64.0 | ||
| High-grade | 4 | 36.4 | 18 | 36.0 | 0.982 | ||
| Laterality of stone | Right | 5 | 45.5 | 25 | 50.0 | ||
| Left | 6 | 54.5 | 25 | 50.0 | 0.785 | ||
| Position of stone | Renal pelvis or PUJ | 2 | 18.2 | 4 | 8.0 | ||
| Upper ureter | 6 | 54.5 | 29 | 58.0 | |||
| Mid ureter | 1 | 9.1 | 8 | 16.0 | |||
| Lower ureter | 2 | 18.2 | 9 | 18.0 | 0.738 | ||
| Size of stone (mm) | Longest diameter | Median [IQR] | 7.0 [5.0–12.0] | 8.0 [6.0–10.0] | 0.806 | ||
| Shortest diameter | Median [IQR] | 4.0 [3.0–8.0] | 5.0 [4.0–7.0] | 0.842 | |||
| Drainage | Ureteral stent | 10 | 90.9 | 46 | 92.0 | ||
| Nephrostomy | 1 | 9.1 | 4 | 8.0 | 0.905 | ||
CCI Charlson Comorbidity Index, PCT Procalcitonin, PSEP Presepsin, PUJ Pelvic ureteral junction
Odds ratio for sepsis in relation to various factors by logistic regression analysis
| Variables | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||||
| Age (yr) | 64≥ | Ref | |||||
| 64< | 3.13 | (0.74–13.20) | 0.120 | ||||
| Gender | Male | Ref | |||||
| Female | 1.93 | (0.46–8.16) | 0.370 | ||||
| Performance status | 0, 1 | Ref | |||||
| 2, 3 | 3.48 | (0.51–23.89) | 0.204 | ||||
| Diabetes mellitus | Negative | Ref | |||||
| Positive | 1.07 | (0.25–4.64) | 0.930 | ||||
| Cardiovascular or neurologic disease | Negative | Ref | |||||
| Positive | 3.00 | (0.71–12.69) | 0.136 | ||||
| Immunocompromised status | Negative | Ref | |||||
| Positive | 2.40 | (0.20–29.10) | 0.492 | ||||
| History of urinary tract abnormalities | Negative | Ref | |||||
| Positive | 1.21 | (0.15–9.82) | 0.860 | ||||
| CCI scores | 0–2 | Ref | |||||
| ≥3 | 5.87 | (1.00–34.39) | 0.050 | ||||
| Serum creatinine (mg/dL) | 1.26≥ | Ref | |||||
| 1.26< | 3.39 | (0.80–14.32) | 0.096 | ||||
| Leukocyte counts (×103/μL) | 13.1≥ | Ref | |||||
| 13.1< | 3.13 | (0.74–13.20) | 0.120 | ||||
| C-reactive protein (mg/dL) | 10.83≥ | Ref | |||||
| 10.83< | 1.20 | (0.32–4.45) | 0.785 | ||||
| Platelet counts (×104/μL) | 15.0≤ | Ref | Ref | ||||
| 15.0> | 15.95 | (3.00–84.92) | 0.001 | 3.23 | (0.39–26.64) | 0.276 | |
| Serum albumin (g/dL) | 3.1≤ | Ref | Ref | ||||
| 3.1> | 5.54 | (1.38–22.24) | 0.016 | 1.21 | (0.15–9.82) | 0.860 | |
| PCT (ng/mL) | 23.55≥ | Ref | Ref | ||||
| 23.55< | 30.67 | (5.75–163.67) | < 0.001 | 13.12 | (1.41–122.03) | 0.024 | |
| PSEP (pg/mL) | 515≥ | Ref | Ref | ||||
| 515< | 23.33 | (2.73–198.87) | 0.004 | 13.13 | (1.07–161.45) | 0.044 | |
CCI Charlson Comorbidity Index, PCT Procalcitonin, PSEP Presepsin, OR Odds ratio, CI Confidence interval